Research in the Caleb Alexander Lab examines prescription drug use. This includes studies of population-based patterns and determinants of pharmaceutical use, clinical decision-making about prescription drugs, and the effect of changes in regulatory and payment policies on pharmaceutical utilization. We have special expertise in conducting survey-based studies and analyzing secondary data sources, including administrative claims, the Medical Expenditure Panel Survey and the National Ambulatory Medical Care Survey.
Dr. Morgan Grams and her colleagues are involved in a wide range of clinical research projects applying quantitative methods to multidimensional data to develop actionable clinical indicators. Along with Dr. Josef Coresh, Dr. Grams leads the Chronic Kidney Disease (CKD) Prognosis Consortium, a global consortium of over 200 investigators and >11 million participants (https://ckdpc.org). They have developed and validated several risk calculators that are now widely used in clinical practice (https://ckdpcrisk.org). She holds a joint appointment in the Bloomberg School of Public Health, where she is a member of the Center of Drug Safety and Effectiveness. Her research in pharmacoepidemiology leverages electronic health records from multiple countries to evaluate the risks and benefits of commonly used medications across the spectrum of kidney function. Together with her team, Dr. Grams also focuses on identifying targetab...le pathways or biomarkers that underlie the development of chronic kidney disease using multi-omic approaches.
Research areas in the Sevil Yasar Lab include dementia, cognitive decline, hydrocephalus and pharmacoepidemiology. Recently, we studied the ability of fatty acid amide hydrolase (FAAH) inhibitors to block the rewarding effects of nicotine in squirrel monkeys.